{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Cancer+Stage+IB&page=2",
    "query": {
      "condition": "Cervical Cancer Stage IB",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Cancer+Stage+IB&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T13:58:13.155Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00577317",
      "title": "Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphedema",
        "Stage 0 Cervical Cancer",
        "Stage 0 Uterine Corpus Cancer",
        "Stage 0 Vulvar Cancer",
        "Stage I Uterine Corpus Cancer",
        "Stage I Vulvar Cancer",
        "Stage IA Cervical Cancer",
        "Stage IB Cervical Cancer",
        "Stage II Uterine Corpus Cancer",
        "Stage II Vulvar Cancer",
        "Stage IIA Cervical Cancer",
        "Stage IIB Cervical Cancer",
        "Stage III Cervical Cancer",
        "Stage III Uterine Corpus Cancer",
        "Stage III Vulvar Cancer",
        "Stage IV Uterine Corpus Cancer",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer",
        "Stage IVB Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "Management of Therapy Complications",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2007-12",
      "completion_date": "2009-07-27",
      "has_results": true,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577317"
    },
    {
      "nct_id": "NCT03019003",
      "title": "Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Oral Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "5' Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2017-03-20",
      "completion_date": "2024-09-24",
      "has_results": true,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03019003"
    },
    {
      "nct_id": "NCT02113878",
      "title": "Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell of Head and Neck",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Hypopharyngeal Cancer",
        "Early Invasive Cervical Squamous Cell Carcinoma",
        "Carcinoma of Larynx",
        "Cancer of Nasopharynx"
      ],
      "interventions": [
        {
          "name": "BKM120",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-modulated radiotherapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2014-09-29",
      "completion_date": "2022-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113878"
    },
    {
      "nct_id": "NCT03236935",
      "title": "Phase Ib of L-NMMA and Pembrolizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Malignant Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Classical Hodgkin Lymphoma",
        "Urothelial Carcinoma Bladder",
        "DNA Repair-Deficiency Disorders"
      ],
      "interventions": [
        {
          "name": "L-NMMA",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-08-27",
      "completion_date": "2022-04-22",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03236935"
    },
    {
      "nct_id": "NCT06236425",
      "title": "TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck",
        "Metastatic Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TBio-4101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Platinum based chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2024-03-14",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06236425"
    },
    {
      "nct_id": "NCT00978874",
      "title": "Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "fludeoxyglucose F 18",
          "type": "RADIATION"
        },
        {
          "name": "fluorine F 18 EF5",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2008-05",
      "completion_date": "2013-09-04",
      "has_results": true,
      "last_update_posted_date": "2021-06-25",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00978874"
    },
    {
      "nct_id": "NCT06211335",
      "title": "Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Recurrent Head and Neck Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Refractory Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Losartan",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-12-07",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Aurora, Colorado",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06211335"
    },
    {
      "nct_id": "NCT03260023",
      "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HPV-Related Carcinoma",
        "HPV-Related Cervical Carcinoma",
        "HPV-Related Anal Squamous Cell Carcinoma",
        "HPV-Related Penile Squamous Cell Carcinoma",
        "HPV-Related Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TG4001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Transgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2017-09-01",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03260023"
    },
    {
      "nct_id": "NCT01414608",
      "title": "Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Adenocarcinoma",
        "Cervical Adenosquamous Carcinoma",
        "Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Stage IB Cervical Cancer AJCC v6 and v7",
        "Stage IIA Cervical Cancer AJCC v7",
        "Stage IIB Cervical Cancer AJCC v6 and v7",
        "Stage IIIB Cervical Cancer AJCC v6 and v7",
        "Stage IVA Cervical Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GOG Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 926,
      "start_date": "2012-01-09",
      "completion_date": "2021-07-09",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 315,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01414608"
    },
    {
      "nct_id": "NCT07594626",
      "title": "BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Biliary Tract Carcinoma",
        "Metastatic Colon Carcinoma",
        "Metastatic Esophageal Carcinoma",
        "Metastatic Malignant Digestive System Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Pancreatic Carcinoma",
        "Stage IV Colon Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "PRMT5 Inhibitor BMS-986504",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2027-12-09",
      "completion_date": "2030-12-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-07-21T13:58:13.155Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07594626"
    }
  ]
}